Gilead Sciences Inc. (NASDAQ: GILD) reported its fourth-quarter earnings after the markets closed on Tuesday. The company posted $2.70 in earnings per share (EPS) and $7.3 billion in revenue, compared with the…
Chris Lange Gilead Sciences is set to report its fourth-quarter financial results after the markets close on Tuesday.
Chris Lange 24/7 Wall St. has put together a preview of GM, Twitter, NVIDIA and some of the major companies reporting their quarterly results this week as earnings season winds down.
With stocks at all-time highs, perhaps there may be some better safety in companies that are known and that offer "value" as well. It is this value segment that has come front…
As we approached Trump’s inauguration, the health care sector in general rallied. Now it’s time to see what the bears have to say about this rally.
DryShips, Gilead Sciences, BT Group, and Cascadian Therapeutics made new 52-week lows on Tuesday.
Paul Ausick DryShips, Teva, Endo Pharma, and Gilead Sciences posted new 52-week lows Monday.
A new Jefferies research report makes the case that while market parameters are indeed expensive, there still are cheap stocks to buy that have a large enough market cap to provide some…
As we have approached Trump’s inauguration, the health care sector in general has rallied. Now it’s time to see what the bears have to say about this rally.
Needless to say, the past two years have been rough on biotech. The question for investors is which of the stocks hold the best potential in 2017.
The December 15 short interest data have been compared with the previous report, and short interest was down in most of the selected biotech stocks.
The November 30 short interest data have been compared with the previous report, and short interest was mixed in the selected biotech stocks.
December 8, 2016: Here are four stocks trading with relatively heavy volume among 34 equities making new 52-week lows in Thursday’s session. On the NYSE, advancers led decliners by about 3 to…
The November 15 short interest data have been compared with the previous report, and short interest increased in most of the selected biotech stocks.
Gilead Sciences has announced that the FDA has approved its once-a-day treatment for adults with chronic hepatitis B virus infection.
Jon C. Ogg 